|Confidence|

Our Vision

COMBiNATi believes that cancer will someday become a manageable chronic condition, instead of a deadly disease. With high throughput sequencing tools, it has become easier than ever to detect cancer early on. Using innovative strategies, growing numbers of targeted therapeutics have already been put into the development pipeline. However, for any chronic disease, successful monitoring of treatment efficacy and recurrence hinges on the timely and accurate quantification of disease-relevant biomarkers. COMBiNATi can become the leader in cancer recurrence monitoring by enabling patients and clinicians to have |confidence| when it comes to keeping an eye on cancer.

Our Values

Champion

Winning mentality

Resilience

If it was easy, it would be done already

Empowering

Bring out the absolute best in each other

Agility

Rapid adaptation based on facts and data

Thoughtfulness

Awareness of customer needs

Empathy

Patient centered solutions

CREATE

Notable Events:

August 2016

Incorporation of COMBiNATi

October 2016

COMBiNATi receives Thermo Innovation Award

December 2016

First COMBiNATi patent granted

February 2018

COMBiNATi receives SLAS Innovation Award

March 2018

COMBiNATi receives Phase 1 SBIR Grant from National Cancer Institute

August 2018

COMBiNATi receives Phase 2 SBIR Grant from National Institute of Health Office of Directors